Kim Rivers Sells 136,811 Shares of Trulieve Cannabis (NYSE:TRLV) Stock

Posted by ABMN Staff on Jun 28th, 2026

Trulieve Cannabis Corp. (NYSE:TRLV – Get Free Report) CEO Kim Rivers sold 136,811 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $8.76, for a total transaction of $1,198,464.36. Following the sale, the chief executive officer directly owned 1,476,913 shares in the company, valued at approximately $12,937,757.88. This represents a 8.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Trulieve Cannabis Stock Up 4.8%

Shares of Trulieve Cannabis stock opened at $8.93 on Friday. Trulieve Cannabis Corp. has a 12-month low of $3.50 and a 12-month high of $13.28.

Key Headlines Impacting Trulieve Cannabis

Here are the key news stories impacting Trulieve Cannabis this week:

Negative Sentiment: CEO Kim Rivers sold 136,811 shares for about $1.2 million, adding to concerns that management may be taking advantage of the stock’s recent strength. Trulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in One Year
Neutral Sentiment: Multiple reports highlighted additional CEO stock sales from earlier in the week, including 300,000 shares on June 25 and 400,000 shares on June 24, reinforcing the theme of heavy insider selling. Insider Selling: Trulieve Cannabis (NYSE:TRLV) CEO Sells $2,451,000.00 in Stock
Neutral Sentiment: Trulieve announced the planned termination of an executive automatic securities disposition plan, which may simply reflect a change in future insider-sale mechanics rather than a direct change in fundamentals. Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan
Neutral Sentiment: Investor commentary also noted Trulieve among “promising” or “best” cannabis stocks to watch, but these mentions were broad sector pieces and did not include a company-specific catalyst. Promising Cannabis Stocks To Follow Today – June 26th

Wall Street Analyst Weigh In

TRLV has been the topic of several research reports. Zacks Research raised Trulieve Cannabis to a “hold” rating in a research report on Thursday, June 18th. Weiss Ratings initiated coverage on Trulieve Cannabis in a research report on Tuesday, June 16th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Trulieve Cannabis presently has an average rating of “Reduce”.

Check Out Our Latest Research Report on Trulieve Cannabis

About Trulieve Cannabis

(Get Free Report)

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.